Meriofert Kit

Follicle-Stimulating Hormone; Luteinising Hormone, the active ingredients in Meriofert Kit, are gonadotropins presented as an injectable kit for intramuscular or subcutaneous use. They are employed to treat infertility caused by anovulation and to support controlled ovarian stimulation in assisted reproductive technologies.

GNH USA supplies Meriofert Kit as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, fertility centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for biologic products. Customers benefit from comprehensive regulatory support and timely delivery across EU and global markets.

Meriofert Kit, a gonadotropin preparation, is used in reproductive endocrinology to stimulate ovarian follicle development. - Infertility due to anovulation: induces follicular growth and ovulation to improve chances of conception. - Controlled ovarian stimulation for IVF: supports the development of multiple mature follicles for egg retrieval in in‑vitro fertilisation cycles. - Ovulation induction for intrauterine insemination (IUI): enhances follicular response to increase the likelihood of successful insemination.

Administration of Meriofert Kit may be associated with a range of adverse reactions.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the site of administration. - Headache: transient headache occurring shortly after dosing. - Nausea: mild gastrointestinal upset. - Ovarian hyperstimulation symptoms: abdominal bloating, mild pelvic discomfort.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS): severe fluid shift, ascites, thromboembolism. - Allergic reaction: rash, urticaria, or anaphylaxis. - Visual disturbances: blurred vision or retinal changes.

Clinicians should consider several precautions when prescribing Meriofert Kit to ensure patient safety. - Patient selection: assess baseline ovarian reserve and contraindications before initiating therapy. - Monitoring: perform regular ultrasound and estradiol measurements to detect excessive response. - Hormone-sensitive conditions: avoid use in patients with active estrogen‑dependent tumors. - Thromboembolic risk: evaluate history of clotting disorders as gonadotropins may increase risk. - Medication interactions: review concurrent use of hormonal contraceptives or other fertility drugs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert Kit can interact with other agents that affect hormonal balance or ovarian response.

Major Interactions (Avoid): - Hormonal contraceptives: may blunt the ovarian response and reduce efficacy. - GnRH agonists/antagonists: concurrent use can lead to unpredictable follicular development.

Moderate Interactions (Monitor Closely): - Thyroid hormone therapy: gonadotropins may alter thyroid function tests. - Anticoagulants: increased risk of ovarian cyst rupture may require monitoring. - Aromatase inhibitors: may affect estradiol levels and require dose adjustment.